109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
恩格列净可提高社区 2 型糖尿病患者血清及唾液中高分子量脂联素水平
Authors Xu L, Niu C, Liu Y, Li X, Wang Z, Yin J, Li M, Wu Q, Liu M, Sun L, Xu M, Yang J, Zhang J
Received 20 June 2025
Accepted for publication 25 September 2025
Published 15 October 2025 Volume 2025:18 Pages 6211—6219
DOI https://doi.org/10.2147/IJGM.S548438
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Woon-Man Kung
Linxin Xu,1– 3,* Chunfan Niu,4,* Yun Liu,5 Xiaoyu Li,6 Zhengqian Wang,4 Jianhong Yin,1– 3 Mina Li,1 Qianqian Wu,1– 3 Ming Liu,1– 3 Li Sun,1– 3 Minggang Xu,7 Jing Yang,1 Jin Zhang1,2
1Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 2Shanxi Innovation Center for Integrated Management of Hypertension, Hyperlipidemia and Hyperglycemia Correlated with Cardiovascular and Cerebrovascular Diseases, Taiyuan, Shanxi, People’s Republic of China; 3Clinical Research Center for Metabolic Diseases of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 4First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 5Department of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 6Academy of medical Science, Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 7Department of Endocrinology, Changzhi Second People’s Hospital, Changzhi, Shanxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jing Yang, Email yangjlm@126.com Jin Zhang, Email 394064598@qq.com
Purpose: To investigate Henagliflozin’s effect on high-molecular-weight (HMW) adiponectin in serum and saliva of type 2 diabetes mellitus (T2DM) patients.
Patients and Methods: This study included 66 patients with T2DM consecutively recruited from two community health service stations in southeastern Shanxi Province between December 2023 and November 2024, along with 66 healthy individuals as the normal control group. T2DM patients with glycated hemoglobin A1c (HbA1c) > 7% and without drug treatment received henagliflozin (10 mg once daily) for 12 weeks. The general data of the two groups before and after treatment were collected and the clinical indicators were detected, including body mass index (BMI), waist circumference, fasting plasma glucose (FPG), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), etc. At the same time, the blood and salivary samples of the two groups were collected before and after treatment, and the levels of HMW adiponectin in serum and saliva were detected by ELISA. Statistical comparisons were performed using paired or unpaired t-tests for normally distributed variables and the Mann-Whitney U test for non-normally distributed ones. The correlation between serum and saliva HMW adiponectin levels was assessed using Spearman’s rank correlation. Furthermore, stepwise linear regression was employed to identify factors affecting HMW adiponectin levels in serum and saliva.
Results: Compared with the healthy control group, the serum and salivary levels of HMW adiponectin were decreased in T2DM patients (4.10 (2.30,6.80) VS 3.70 (1.55,5.65), 2.35 (0.87,5.80) VS 1.80 (0.72,4.53), P < 0.05). T2DM patients treated with henggliflozin for 12 weeks exhibited significant increases in both serum and salivary HMW adiponectin levels (3.70 (1.55,5.65) VS 4.70 (2.65,8.60), 1.80 (0.72,4.53) VS 3.85 (1.88,10.33), p < 0.05). Furthermore, significant improvements were observed in multiple metabolic parameters, including reductions in DBP, BMI, TC and TG (p < 0.05). A weak but statistically significant correlation was found between serum and salivary adiponectin levels (r = 0.210, R² = 0.044; p < 0.05). In order to reveal the influence factors of adiponectin in serum and saliva, linear stepwise regression analysis showed that waist circumference was an independent risk factor for adiponectin in serum (95% CI: − 0.087, − 0.015; P < 0.05), and gender was an independent risk factor for adiponectin in saliva (95% CI: − 4.663, − 0.529; P < 0.05).
Conclusion: In our study, serum and salivary HMW adiponectin levels were decreased in patients with T2DM, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors could improve serum and salivary HMW adiponectin levels after treatment, which is expected to be a major target for diabetes treatment.
Keywords: serum, saliva, high-molecular-weight adiponectin, HMW adiponectin, type 2 diabetes mellitus, sodium-glucose co-transporter-2 inhibitors
1Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 2Shanxi Innovation Center for Integrated Management of Hypertension, Hyperlipidemia and Hyperglycemia Correlated with Cardiovascular and Cerebrovascular Diseases, Taiyuan, Shanxi, People’s Republic of China; 3Clinical Research Center for Metabolic Diseases of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 4First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 5Department of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 6Academy of medical Science, Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 7Department of Endocrinology, Changzhi Second People’s Hospital, Changzhi, Shanxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jing Yang, Email yangjlm@126.com Jin Zhang, Email 394064598@qq.com
Purpose: To investigate Henagliflozin’s effect on high-molecular-weight (HMW) adiponectin in serum and saliva of type 2 diabetes mellitus (T2DM) patients.
Patients and Methods: This study included 66 patients with T2DM consecutively recruited from two community health service stations in southeastern Shanxi Province between December 2023 and November 2024, along with 66 healthy individuals as the normal control group. T2DM patients with glycated hemoglobin A1c (HbA1c) > 7% and without drug treatment received henagliflozin (10 mg once daily) for 12 weeks. The general data of the two groups before and after treatment were collected and the clinical indicators were detected, including body mass index (BMI), waist circumference, fasting plasma glucose (FPG), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), etc. At the same time, the blood and salivary samples of the two groups were collected before and after treatment, and the levels of HMW adiponectin in serum and saliva were detected by ELISA. Statistical comparisons were performed using paired or unpaired t-tests for normally distributed variables and the Mann-Whitney U test for non-normally distributed ones. The correlation between serum and saliva HMW adiponectin levels was assessed using Spearman’s rank correlation. Furthermore, stepwise linear regression was employed to identify factors affecting HMW adiponectin levels in serum and saliva.
Results: Compared with the healthy control group, the serum and salivary levels of HMW adiponectin were decreased in T2DM patients (4.10 (2.30,6.80) VS 3.70 (1.55,5.65), 2.35 (0.87,5.80) VS 1.80 (0.72,4.53), P < 0.05). T2DM patients treated with henggliflozin for 12 weeks exhibited significant increases in both serum and salivary HMW adiponectin levels (3.70 (1.55,5.65) VS 4.70 (2.65,8.60), 1.80 (0.72,4.53) VS 3.85 (1.88,10.33), p < 0.05). Furthermore, significant improvements were observed in multiple metabolic parameters, including reductions in DBP, BMI, TC and TG (p < 0.05). A weak but statistically significant correlation was found between serum and salivary adiponectin levels (r = 0.210, R² = 0.044; p < 0.05). In order to reveal the influence factors of adiponectin in serum and saliva, linear stepwise regression analysis showed that waist circumference was an independent risk factor for adiponectin in serum (95% CI: − 0.087, − 0.015; P < 0.05), and gender was an independent risk factor for adiponectin in saliva (95% CI: − 4.663, − 0.529; P < 0.05).
Conclusion: In our study, serum and salivary HMW adiponectin levels were decreased in patients with T2DM, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors could improve serum and salivary HMW adiponectin levels after treatment, which is expected to be a major target for diabetes treatment.
Keywords: serum, saliva, high-molecular-weight adiponectin, HMW adiponectin, type 2 diabetes mellitus, sodium-glucose co-transporter-2 inhibitors